Accessibility Menu
 
Dianthus Therapeutics logo

Dianthus Therapeutics

(NASDAQ) DNTH

Current Price$86.18
Market Cap$4.71B
Since IPO (2023)+683%
5 Year-51%
1 Year+360%
1 Month-10%

Dianthus Therapeutics Financials at a Glance

Market Cap

$4.71B

Revenue (TTM)

$1.34M

Net Income (TTM)

$11.32M

EPS (TTM)

$-4.14

P/E Ratio

-20.82

Dividend

$0.00

Beta (Volatility)

1.03 (Average)

Price

$86.18

Volume

612,370.704

Open

$83.59

Previous Close

$86.16

Daily Range

$81.23 - $87.22

52-Week Range

$16.64 - $96.50

DNTH: Motley Fool Moneyball Superscore

72

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Dianthus Therapeutics

Industry

Biotechnology

Employees

92

CEO

Marino Garcia, MBA

Headquarters

New York City, NY 10036, US

DNTH Financials

Key Financial Metrics (TTM)

Gross Margin

94%

Operating Margin

-143%

Net Income Margin

-8%

Return on Equity

-23%

Return on Capital

-16%

Return on Assets

-1%

Earnings Yield

-4.80%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.71B

Shares Outstanding

54.67M

Volume

612.37K

Avg. Volume

932.73K

Financials (TTM)

Gross Profit

$2.04M

Operating Income

$177.93M

EBITDA

$177.93M

Operating Cash Flow

$129.06M

Capital Expenditure

$213.00K

Free Cash Flow

$129.27M

Cash & ST Invst.

$404.30M

Total Debt

$1.39M

Dianthus Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$463.00K

-60.2%

Gross Profit

$387.00K

-66.7%

Gross Margin

83.59%

N/A

Market Cap

$4.71B

N/A

Market Cap/Employee

$60.39M

N/A

Employees

78

N/A

Net Income

$40.83M

-38.4%

EBITDA

$46.53M

-40.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$1.11B

+323.9%

Accounts Receivable

$1.31M

+31.3%

Inventory

$0.00

N/A

Long Term Debt

$965.00K

-17.5%

Short Term Debt

$399.00K

+76.5%

Return on Assets

-0.91%

N/A

Return on Invested Capital

-15.83%

N/A

Free Cash Flow

$28.87M

-4.4%

Operating Cash Flow

$28.86M

-4.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ANABAnaptysBio, Inc.
$63.15+1.54%
ELVNEnliven Therapeutics, Inc.
$41.34-4.04%
OCSOculis Holding AG
$30.29+0.23%
TSHATaysha Gene Therapies, Inc.
$5.96-5.40%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$13.95-0.04%
FFord Motor Company
$13.40-0.07%
POETPoet Technologies
$15.97-0.22%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$15.06-0.10%

Questions About DNTH

What is the current price of Dianthus Therapeutics?

Dianthus Therapeutics is trading at $86.16 per share.

What is the 52-week range for Dianthus Therapeutics?

Over the past 52 weeks, Dianthus Therapeutics has traded between $16.64 and $96.50.

How much debt does Dianthus Therapeutics have?

As of the most recent reporting period, Dianthus Therapeutics reported total debt of $1.36M.

How much cash does Dianthus Therapeutics have on hand?

Dianthus Therapeutics reported $627.67M in cash and cash equivalents in its most recent financial results.

What is Dianthus Therapeutics’s dividend yield?

Dianthus Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.